Form 8-K
8-K — PERRIGO Co plc
Accession: 0001193125-26-261809
Filed: 2026-06-08
Period: 2026-06-07
CIK: 0001585364
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — d102437d8k.htm (Primary)
EX-99.1 (d102437dex991.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: d102437d8k.htm · Sequence: 1
8-K
PERRIGO Co plc 00-0000000 353 false 0001585364 0001585364 2026-06-07 2026-06-07 0001585364 prgo:OrdinaryShares0001ParValueMember 2026-06-07 2026-06-07 0001585364 prgo:A4.900SeniorNotesDueJune152030Member 2026-06-07 2026-06-07 0001585364 prgo:A6.125SeniorNotesDue2032Member 2026-06-07 2026-06-07 0001585364 prgo:A5.375SeniorNotesDue2032Member 2026-06-07 2026-06-07 0001585364 prgo:A5.30UnsecuredSeniorNotesDueNovember152043Member 2026-06-07 2026-06-07 0001585364 prgo:A49SeniorLoanDue2024Member 2026-06-07 2026-06-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 7, 2026
Perrigo Company plc
(Exact name of registrant as specified in its charter)
Commission file number 001-36353
Ireland
Not Applicable
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74
+353 1 7094000
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Ordinary shares, €0.001 par value
PRGO
New York Stock Exchange
4.900% Notes due 2030
PRGO30
New York Stock Exchange
6.125% Notes due 2032
PRGO32A
New York Stock Exchange
5.375% Notes due 2032
PRGO32B
New York Stock Exchange
5.300% Notes due 2043
PRGO43
New York Stock Exchange
4.900% Notes due 2044
PRGO44
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of Patrick Lockwood-Taylor
On June 7, 2026, Patrick Lockwood-Taylor resigned, effective immediately, as President and Chief Executive Officer and as a member of the Board of Directors (the “Board”) of Perrigo Company plc (the “Company”). This resignation follows a determination by the Board that certain personal conduct was not consistent with the Company’s Code of Conduct and core values. Consequently, the Board has reduced the number of directors constituting the Board from 9 to 8.
Mr. Lockwood-Taylor’s resignation is not related to the Company’s business, strategy, operations, financial reporting, or results of operations.
Appointment of Interim President and Chief Executive Officer
On June 7, 2026, the Board appointed Albert A. Manzone, Director and member of the Audit Committee of the Board, as the Company’s Interim President and Chief Executive Officer. Concurrently, the Board has initiated a comprehensive search process to identify a permanent President and Chief Executive Officer.
Mr. Manzone’s biography is set forth under the heading “Election of Directors - About the Nominated Directors” in the Company’s Proxy Statement for the 2026 Annual Meeting of Shareholders, filed with the Securities and Exchange Commission on March 20, 2026, which information is incorporated herein by reference.
In connection with his appointment, Mr. Manzone will step down as a member of the Audit Committee during the time of his service as the Interim President and Chief Executive Officer. In addition, Mr. Manzone will step down as Deputy Chief Executive Officer of Monte-Carlo Society des Bains de Mer.
Compensatory arrangements relating to Mr. Manzone’s service as Interim President and Chief Executive Officer of the Company have not been definitively determined as of the date hereof. The Company will provide disclosure of the material terms of such arrangements on an amendment to this current report on Form 8-K within four business days after they become available.
There are no family relationships between Mr. Manzone and any Company director or executive officer, and no arrangements or understandings between Mr. Manzone and any other person pursuant to which he was selected as an officer. Since January 1, 2025, there have been no transactions, and there are no currently proposed transactions, to which the Company was or is a participant and in which Mr. Manzone had or is to have a direct or indirect material interest that would require disclosure pursuant to Item 404(a) of Regulation S-K.
Item 7.01.
Regulation FD Disclosure.
The Company’s press release regarding the matter described in Item 5.02 above is attached hereto as Exhibit 99.1.
The information in this Item 7.01, including the exhibit attached hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
99.1
Press Release issued by Perrigo Company plc on June 8, 2026 furnished solely pursuant to Item 7.01 of Form 8-K.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 8, 2026
PERRIGO COMPANY PLC
By:
/s/ Charles Atkinson
Name:
Charles Atkinson
Title:
General Counsel & Company Secretary
EX-99.1
EX-99.1
Filename: d102437dex991.htm · Sequence: 2
EX-99.1
Exhibit 99.1
Perrigo Announces Leadership Transition
Albert A. Manzone Appointed Interim President and CEO
Patrick Lockwood-Taylor Resigns as President and CEO and as a Member of the Board
DUBLIN, June 8, 2026 – Perrigo Company plc (NYSE: PRGO) (“Perrigo” or the “Company”), a leading provider of Consumer
Self-Care Products, today announced that its Board of Directors has appointed Albert A. Manzone, a member of the Company’s Board, as Interim President and Chief Executive Officer, effective immediately. The Board has initiated a comprehensive
search process to identify a permanent successor.
Patrick Lockwood-Taylor has resigned as President and CEO, and as a member of the Board, effective
immediately. This resignation follows a determination by the Board of Directors that certain personal conduct by Mr. Lockwood-Taylor was not consistent with the Company’s Code of Conduct and core values. The conduct did not involve the
Company’s business, strategy, operations, financial reporting, or results of operations.
Orlando D. Ashford, Chair of Perrigo’s Board of
Directors, said, “Perrigo’s core values are foundational to how we operate, and the Board expects all colleagues – especially our senior leaders – to uphold those standards at all times. The Board acted decisively and has
full confidence in Albert, who brings more than 30 years of global leadership experience and a proven track record of transforming businesses at inflection points and creating value as well as deep knowledge of our business, people, and self-care
platform. The Company has made significant progress in advancing our strategy in recent years, stabilizing and streamlining the business and implementing our new commercial operating model and the Board remains confident in Perrigo’s outlook.
As we move forward, we believe Albert is the right leader to guide Perrigo through this transition and work with the broader leadership team to continue strengthening our company and deliver enhanced value for shareholders.”
Albert A. Manzone, Interim President and CEO of Perrigo, said, “I have served on Perrigo’s Board since 2022, and I know this company well —
its self-care platform, its people, and the clear progress we have made on our strategy. My priority as interim CEO is continuity: to keep that strategy on course and to support a talented leadership team as we sustain our momentum on value
creation. I look forward to working closely with the Board and the team in the months ahead.”
Perrigo also reaffirmed its full-year 2026 outlook
provided in its first quarter 2026 earnings press release issued on May 6, 2026, including All In net sales growth of (5.5)% to (1.5)%, All In adjusted EPS of $2.00 to $2.30, Core net sales growth of (3.0)% to +1.0% and Core adjusted EPS of
$2.25 to $2.55.
About Albert A. Manzone
Albert A. Manzone is a global executive with more than 30 years of leadership experience across consumer goods, consumer health, luxury and hospitality. He has
led businesses at global scale, with a track record of transforming companies at inflection points and creating value. He has served as a member of the Perrigo Board of Directors since 2022. Most recently, he was Deputy Chief Executive Officer of
Monte-Carlo Société des Bains de Mer, a premier luxury hospitality group, where he drove operational performance and strengthened the leadership team across three consecutive record years. Previously, he served as Chief Executive
Officer of Whole Earth Brands, a global food company. Earlier in his career, he was President Europe at Oettinger Davidoff AG and held senior leadership roles at Novartis Consumer Health, W.M. Wrigley Jr. Company, PepsiCo, and McKinsey &
Company. He currently serves as a director at Syntec Optics Holdings (NASDAQ: OPTX). He holds an MBA from the Kellogg School of Management at Northwestern University and a postgraduate degree in international business from Sorbonne University.
About Perrigo
Perrigo Company plc (NYSE: PRGO) is a
leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to
proactively prevent or treat conditions that can be self-managed.
For more information, visit www.perrigo.com.
Forward-Looking Statements
Certain statements in this
press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our
future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry’s actual results, levels of activity, performance or achievements to be materially different from those
expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In
some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “forecast,” “predict,” “potential” or the negative of those terms or other comparable terminology. We have based these
forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and
involve known and unknown risks and uncertainties, many of which are beyond our control, including: the impact of the leadership transition described herein on our relationships with investors, employees, suppliers, wholesalers, lenders and other
stakeholders; our ability to complete the proposed divestment of the Dermacosmetics branded business, receipt of works council and regulatory approval regarding the transaction, performance by counterparties to the transaction and the likelihood of
satisfying the deferred payment milestones associated with the transaction, supply chain impacts on our business, including those caused or exacerbated by armed conflict, trade and other economic sanctions and/or disease; general economic, credit,
and market conditions; increased or new tariffs by the U.S. or foreign governments (and any retaliatory or reciprocal tariffs) and changes in global trade relations; the impact of the war in Ukraine and any escalation thereof, including the effects
of economic and political
sanctions imposed by the United States, United Kingdom, European Union, and other countries related thereto; the outbreak or escalation of conflict in other regions where we do business,
including the ongoing conflict and social, political and economic environment in Israel and the broader Middle East; current and future impairment charges, if we determine that the carrying amount of specific assets may not be recoverable from the
expected future cash flows of such assets; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing
pressures from customers and consumers; resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives; uncertainty regarding our ability to obtain and maintain our
regulatory approvals; potential costs and reputational impact of product recalls or sales halts; potential adverse changes to U.S. and foreign tax, healthcare and other government policy; the effect of epidemic or pandemic disease; the timing,
amount and cost of any share repurchases (or the absence thereof) and/or any refinancing of outstanding debt at or prior to maturity; fluctuations in currency exchange rates and interest rates; receipt of potential earnout payments in connection
with the sale of the HRA Rare Diseases Business and the risk that potential costs or liabilities incurred or retained in connection with this transaction may exceed our estimates or adversely affect our business or operations; the risk that
potential costs or liabilities incurred or retained in connection with the sale of our Rx business may exceed our estimates or adversely affect our business or operations; the consummation and success of other announced and unannounced acquisitions
or dispositions, and our ability to realize the desired benefits thereof; and our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including our ability to
achieve the expected benefits from our ongoing restructuring programs and strategic review processes described herein. Adverse results with respect to pending litigation could have a material adverse impact on our operating results, cash flows and
liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corporate purposes. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially
from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Perrigo Contacts
Eric Jacobson, Vice President, Global Investor Relations
eric.jacobson@perrigo.com
Nick Gallagher, Associate
Director, Global Investor Relations
nicholas.gallagher@perrigo.com
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Document and Entity Information
Jun. 07, 2026
Document And Entity Information [Line Items]
Entity Registrant Name
PERRIGO Co plc
Entity Tax Identification Number
00-0000000
Country Region
353
Amendment Flag
false
Entity Central Index Key
0001585364
Document Type
8-K
Document Period End Date
Jun. 07, 2026
Entity File Number
001-36353
Entity Incorporation State Country Code
L2
Entity Address, Address Line One
The Sharp Building
Entity Address, Address Line Two
Hogan Place
Entity Address, City or Town
Dublin 2
Entity Address, Country
IE
Entity Address, Postal Zip Code
D02 TY74
City Area Code
353 1
Local Phone Number
7094000
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Entity Emerging Growth Company
false
Ordinary Shares 0001 Par Value [Member]
Document And Entity Information [Line Items]
Security 12b Title
Ordinary shares, €0.001 par value
Trading Symbol
PRGO
Security Exchange Name
NYSE
A 4.900 Senior Notes Due June 152030 [Member]
Document And Entity Information [Line Items]
Security 12b Title
4.900% Notes due 2030
Trading Symbol
PRGO30
Security Exchange Name
NYSE
A 6.125 Senior Notes Due 2032 [Member]
Document And Entity Information [Line Items]
Security 12b Title
6.125% Notes due 2032
Trading Symbol
PRGO32A
Security Exchange Name
NYSE
A 5.375 Senior Notes Due 2032 [Member]
Document And Entity Information [Line Items]
Security 12b Title
5.375% Notes due 2032
Trading Symbol
PRGO32B
Security Exchange Name
NYSE
A 5.30 Unsecured Senior Notes Due November 152043 [Member]
Document And Entity Information [Line Items]
Security 12b Title
5.300% Notes due 2043
Trading Symbol
PRGO43
Security Exchange Name
NYSE
A 49 Senior Loan Due 2024 [Member]
Document And Entity Information [Line Items]
Security 12b Title
4.900% Notes due 2044
Trading Symbol
PRGO44
Security Exchange Name
NYSE
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Region code of country
+ References
No definition available.
+ Details
Name:
dei_CountryRegion
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
ISO 3166-1 alpha-2 country code.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCountry
Namespace Prefix:
dei_
Data Type:
dei:countryCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- References
No definition available.
+ Details
Name:
prgo_DocumentAndEntityInformationLineItems
Namespace Prefix:
prgo_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=prgo_OrdinaryShares0001ParValueMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=prgo_A4.900SeniorNotesDueJune152030Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=prgo_A6.125SeniorNotesDue2032Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=prgo_A5.375SeniorNotesDue2032Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=prgo_A5.30UnsecuredSeniorNotesDueNovember152043Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=prgo_A49SeniorLoanDue2024Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: